Kinsale Capital Group, Inc. KNSL
Composite 63/100; the shares have moved about 36% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Income ranks 35/100 — a moderate mark against it.
Quality ranks 74/100 — a moderate point in its favour. Balance-sheet strength ranks 70/100 — a moderate point in its favour. Growth ranks 68/100 — a moderate point in its favour.
Income ranks 35/100 — a moderate mark against it. Momentum ranks 37/100 — a moderate mark against it.
What the company does Kinsale Capital Group (KNSL) underwrites specialty property and casualty insurance across all 50 states, Puerto Rico, and the U.S. Virgin Islands via independent brokers, offering both commercial lines (e.g., excess casualty, construction, energy) and high-value personal lines.
Key financials KNSL posts strong profitability metrics: ROE 30.3%, ROA 7.6%, gross margin 31.1%, operating margin 40.7%, and net margin 28.5%. Revenue and EPS growth stand at 16.8% and 34.0%, respectively, with a 12.1% FCF yield and debt/equity of 0.11.
Stock health Sidera’s overall score is 64.9 (Strong quality, attractively valued, weak momentum), with Quality 75.1 and Valuation 77.4, but Momentum at 30.7. The stock is down 26.48% from its 52-week high and has an RSI(14) of 56.00.
Price vs fair value KNSL trades at a PREMIUM of 14.20% versus our fair-value estimate of 305.49 and a PREMIUM of 1.71% versus the 12-month target of 349.78. - Recent articles highlight rising challenges and valuation concerns (Insider Monkey, Simply Wall St). - Analysts emphasize underwriting discipline and profitability amid a soft market (StockStory). - Technical breakouts above 20- and 200-day moving averages suggest short-term momentum (Zacks).
Looking forward Forward P/E of 16.86 and PEG of 1.12 reflect expectations for continued growth, though momentum remains weak. The low dividend yield (0.2%) and payout ratio (3.4%) suggest capital reinvestment over shareholder returns.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.